Therapeutic agents comprising fusions of insulin and elastic peptides

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Duke University patent solves the following problem:

Therapeutic proteins or peptides in their native state or when recombinantly produced a labile molecules demonstrate, inter alia, short periods of serum stability, serum half-life (ie, circulation half-life ), or limited Persistance body. Such molecules can also be extremely labile when formulated, as when formulated in aqueous solution.

Our analysis of this patent is as follows:

Duke University’s patent US 9458218 B2 deals with Therapeutic agents comprising fusions of insulin and elastic peptides.
The present invention provides therapeutic agents and compositions comprising elastic therapeutic peptides and proteins. Such peptide exhibit a flexible, extended conformation. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist (eg, GLP-1, exendin), insulin, or Factor VII / VIIa, including functional analogs. The present invention further provides polynucleotides encoding, as well as methods of making and using therapeutic agents. The therapeutic agent is improvement in relationship to their use as therapeutics, including, inter alia, one or more of the half-life, clearance and / or body Persistance, solubility, and bioavailability.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Anti-BAFFR antibody formulations

Use PowerPatent’s Online Patent Filing Service to get quick patent protection for your great idea.

The Novartis Pharma Ag patent solves the following problem:

BAFFR: BAFF pattern is critically involved in the maturation of the transitional B-cells, for the salvation and the activation of mature B-cells, and for the isotype class switch in response to T cell-dependent antigens. BAFF and receptor BAFFR important for the survival and growth of malignant B-cells. Furthermore, BAFFR usually not expressed in pre-B cells, but recently shown to express human ALL (B-lineage acute lymphoblastic leukemia) cells (Parameswaran, 2010, Cancer Res. 70 (11) 4346-4356 ). The removal of autoreactive B cells and the blockade should not live / activation mediated by excess BAFF levels in patients suffering from autoimmune disorders or cancer represents a well-validated therapeutic target . Thus, an anti-BAFFR antibody, in particular an antibody capable of antibody-dependent cell-mediated cytotoxicity (ADCC) and blockade of ligand binding BAFFR offer an effective therapeutic agent for autoimmune diseases and B cell neoplasms.

Our analysis of this patent is as follows:

Novartis Pharma Ag’s patent US 9458240 B2 deals with Anti-BAFFR antibody formulations.
Anti-BAFFR antibody formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of antibody active components for delivery to a patient without high levels of antibody aggregation. lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition wherein the antibody has a concentration of at least 50 mg / ml. The lyophilisate or liquid pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and / or a free amino acid.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Monoclonal antibodies and fragment thereof directed against the human anti-mullerian hormone type II receptor (AMHR-II)

File for Quick & Easy Patent Protection with PowerPatent.

The Institut National De La Sante Et De La Recherche Medicale (Inserm) patent solves the following problem:

Our analysis of this patent is as follows:

Institut National De La Sante Et De La Recherche Medicale (Inserm)’s patent US 9458239 B2 deals with Monoclonal antibodies and fragment thereof directed against the human anti-mullerian hormone type II receptor (AMHR-II).
The present invention relates to monoclonal antibodies and fragments thereof directed against the human Anti-Mllerian hormone receptor type II (AMHR-II) and their use for treating and diagnosing cancer diseases, such as ovarian range cancer.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Chaperonin 10-induced immunomodulation

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Cbio Limited patent solves the following problem:

A central part of the host defense system against invading bacteria, fungal, yeast and viral pathogens involves the successful recognition of the pathogen, or components thereof, with the cellular receptor to induce a signaling cascade resulting in stimulation of the immune system and the production of various cytokines. A family of receptor that plays a key role in this line of defense is the Toll-like receptor (TLR) family. TLRs expressed in immune cells, including monocytes, macrophages, dendritic cells, B cells and granulocytes, and a variety of other types of cells including the endothelium and epithelium. TLR activation of pathogens, or by molecules derived thereof, accelerate the formulation intracellular signaling primarily the result of activation of transcription factor NF-B (begging, 2002, Trends Immunol 23 :. 509-12) and modulation cytokine production. . However, a series of other paths can also cause, including the P38 mitogen activated kinase, c-Jun N-terminal kinase and extracellular signal-related kinase pathway (Flohe et al, 2003, J Immunol 170: 2340-2348; Triantafilou and Triantafilou, 2002, Trends Immunol 23: 301-304).

Our analysis of this patent is as follows:

Cbio Limited’s patent US 9457062 B2 deals with Chaperonin 10-induced immunomodulation.
The present invention relates to methods for modulating Toll-like receptor signaling in a subject, or at least one cell, tissue or organ thereof, methods for treating or preventing a disease or state in a subject, methods for modulating the production and / or secretion of one or more immunomodulators in a subject, or at least one cell, tissue or organ thereof, wherein said method includes the administration chaperonin 10, and wherein the chaperonin 10 with a Toll-like receptor activation in a cluster. Also thought related compositions and uses thereof.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Modulators and methods of use

File for Quick & Easy Patent Protection with PowerPatent.

The Stemcentrx, Inc. patent solves the following problem:

Stem and progenitor cell inequality and cell proliferation in the normal process to continue to act in concert to support tissue growth during organogenesis, and cell replacement and repair of the tissues during the entire life of all living organisms. Difference and proliferation decision always controlled in many things and signals that maintain balance in cell fate decisions and tissue architecture. Normal tissue architecture to remain as a result of cells responding to microenvironmental cues that control cell division and tissue maturation. Therefore, cell proliferation and diversity often it is only necessary for the replacement of damaged or dead cells or for growth. Sadly, disruption of cell proliferation and / or divisions resulting from the ten thousand things including, for example, understanding or overabundance of different chemical signals, before changing microenvironments, genetic mutation or some combination thereof. When the normal cellular proliferation and / or division or disturbed somewhat disrupted it can lead to various diseases or disorders including cancer.

Our analysis of this patent is as follows:

Stemcentrx, Inc.’s patent US 9458231 B2 deals with Modulators and methods of use.
The new modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat hyperproliferative disorders given.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Immunomedics, Inc. patent solves the following problem:

For many years it was a goal of scientists in the field of specifically targeted drug therapy using monoclonal antibodies (mAbs) for the specific delivery of toxic agents in human cancers. Conjugates of tumor-associated mAbs and suitable toxic agents developed, but have had mixed success in cancer therapy in humans, and virtually no application in other diseases, such as infectious and autoimmune diseases. The toxic agent is most often a chemotherapeutic drug, although particle-emitting radionuclides, or bacterial or plant toxins, also within the framework of mAbs, especially for cancer therapy (Sharkey and Goldenberg, CA Cancer J Clin. 2006 July-Aug.; 56 (4): 226-243) and, more recently, with radioimmunoconjugates for preclinical therapy of certain infectious diseases (Dadachova and Casadevall, QJ Nucl Med mol Imaging 2006; 50 ( 3): 193-204).

Our analysis of this patent is as follows:

Immunomedics, Inc.’s patent US 9458242 B2 deals with Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity.
The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragments. antibody can bind to the EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAP, hľa-DR, or AFP MUC5ac and the immunoconjugate can be administered at a dose between 4 mg / kg and 24 mg / kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg / kg. When administered in specified dosages and schedules, the immunoconjugate could reduce solid tumor size, reduce or eliminate metastases and effective to treat cancer resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

SAA domain-specific antibodies and peptide antagonists and use thereof to treat inflammatory diseases

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The The Feinstein Institute For Medical Research patent solves the following problem:

Throughout this application various publications mentioned in parentheses. Full citations for these references may be found at the end of the specification immediately preceding the claims. The disclosure of these publications, and all the books, patents and patent application publications mentioned here, it included reference in their entireties into the subject application to more fully describe the art of the subject application set .

Our analysis of this patent is as follows:

The Feinstein Institute For Medical Research’s patent US 9458232 B2 deals with SAA domain-specific antibodies and peptide antagonists and use thereof to treat inflammatory diseases.
Isolated Saa peptide, fusion proteins and compositions comprising the same given as domain-specific antibody Saa. Methods of treatment of sepsis and endotoxemia also given.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Methods and apparatuses for printing three dimensional images

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The Virginia Venture Industries, Llc patent solves the following problem:

This invention relates to various methods and apparatuses for printing three-dimensional objects in three-dimensional printers use three-dimensional math / number of three-dimensional objects .

Our analysis of this patent is as follows:

Virginia Venture Industries, Llc’s patent US 9457519 B2 deals with Methods and apparatuses for printing three dimensional images.
System and method for printing a 3D object in a three-dimensional (3D) printer described. The way semi-automatic or automatic describe something in a picture, receive a 3D model that matches said things said 3D model, and send the matched 3D model in a 3D tig -imprinta.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Kits for systems and methods using acoustic radiation pressure

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Life Technologies Corporation patent solves the following problem:

Embodiments of the present invention relate to systems using acoustic radiation pressure.

Our analysis of this patent is as follows:

Life Technologies Corporation’s patent US 9457139 B2 deals with Kits for systems and methods using acoustic radiation pressure.
A kit of reagents for use in an acoustic apparatus includes a first fluid that is a lysis fluid, a second fluid having an acoustic difference greater than the first fluid, and a reagent for the calling of a particle.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Gram-positive bacteria specific binding compounds

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Genentech, Inc., , Aimm Therapeutics B.V. patent solves the following problem:

Program-positive microorganisms cause many systemic infections. An important member of the gram-positive pathogens are Staphylococcus aureus (S. aureus). 20% of the population is a long-term carrier of S. aureus. S. aureus can cause a range of illnesses from minor skin infections, such as pimples, impetigo (may also be caused by streptococcus pyogenes), boils, cellulitis folliculitis, furuncles, carbuncles, scalded skin syndrome and abscesses , life-threatening diseases such as pneumonia, meningitis, osteomyelitis, endocarditis, Toxic shock syndrome (TSS), and septicemia. S. aureus is capable of infecting all kinds of organs and tissues. S. aureus infection occur in immunocompetent as well as in immune compromised people. 50% of infections in US intensive unit care causing pathogen. Three hundred thousand S. aureus infections every year, resulting in 12,000 deaths, reported in the US (see also Moran et al. NEMJ 355, 666-674 (2006)).

Our analysis of this patent is as follows:

Genentech, Inc., , Aimm Therapeutics B.V.’s patent US 9458228 B2 deals with Gram-positive bacteria specific binding compounds.
The present invention provides improved value compounds can specifically bind gram-positive bacteria. Binding compounds which are fully human, so that therapeutic applications of human individuals.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.